Which weight loss injection works the fastest — and what does 'fast' actually mean?

You've found two options and you want to know which one moves the needle sooner

You've probably spent time reading forum threads, comparing packaging photos, and wondering whether one pen is genuinely ahead of the other or whether it's all marketing. It's a reasonable thing to want to know, and the honest answer is that the clinical evidence does lean one way, but not without caveats worth understanding.

Tirzepatide, sold in the UK as Mounjaro, works on two gut-hormone receptors (GIP and GLP-1) rather than one. Semaglutide, sold as Wegovy, targets GLP-1 alone. In practical terms, this dual action appears to produce steeper weight loss curves in trials. The SURMOUNT-1 study, published in the New England Journal of Medicine, reported average body-weight reductions of around 20–21% at the 15 mg tirzepatide dose over 72 weeks. The STEP 1 trial for semaglutide 2.4 mg reported around 15% over 68 weeks. Both figures are averages from people who also made dietary and activity changes alongside the injections.

The more direct comparison came from the SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, which followed 751 adults with obesity and found tirzepatide produced greater average weight loss than semaglutide 2.4 mg over 72 weeks. That is currently the best evidence available for comparing the two side by side. If you want to understand what the fastest weight loss injection actually is based on that evidence, the clinical picture points clearly toward tirzepatide. Whether that translates to you feeling results faster is a different question.

Why 'fastest' depends on when you count from

Both injections start at a dose designed primarily to help your body adjust, not to produce the largest effect. Tirzepatide begins at 2.5 mg, a dose whose job is settling your digestive system, not driving weight loss. Semaglutide starts at 0.25 mg for the same reason. Titration then moves in roughly four-week steps, meaning you may not reach the dose that produces the most noticeable results until three to six months into treatment. Comparing week-two experiences across both medicines tells you very little about which works faster overall.

Some people do notice appetite changes and small scale shifts within the first few weeks. Others find the first one or two doses unremarkable and see more movement once the dose increases. Both experiences are normal. The NHS tirzepatide page is clear that weight loss with these medicines takes time and works alongside lifestyle changes, it is not a rapid purge of weight in the early weeks. Expecting speed at 2.5 mg, then concluding the medicine isn't working, is one of the most common misreadings our prescribers hear about from patients who have tried treatment elsewhere.

The trajectory matters more than the starting gun. Tirzepatide's eventual ceiling in the trial data is higher, but reaching that ceiling takes months of gradual dose increases and consistent use.

What the cost difference tells you, and what it doesn't

Tirzepatide and semaglutide are priced differently in the UK private market, and the gap is not trivial. Since Eli Lilly raised Mounjaro's list price in September 2025 (with the highest-dose pen's list price rising from around £122 to around £330) private providers have priced accordingly, with typical monthly costs ranging roughly £149 to £375 depending on dose and provider. If cost is a factor, our guide to weight loss injection costs breaks down what those figures actually include.

A lower price does not make one medicine slower, and a higher price does not guarantee faster results. What matters clinically is which medicine is appropriate for you, at which dose, and whether it is from a legitimate supply chain. The MHRA has documented seizures of counterfeit weight-loss pens sold without a prescription, a reminder that chasing the cheapest listing is a different risk category entirely from choosing between two licensed medicines through a regulated pharmacy.

Which injection is actually right for you, and how that gets decided

The evidence favours tirzepatide on average weight loss, and the head-to-head trial supports that reading. But clinical decisions are not made from population averages. A prescriber looks at your weight, your health history, any medicines you already take, and whether there are reasons one option suits you better than the other. Someone with a history of pancreatitis or certain GI conditions, for example, needs a careful conversation before starting either. Pregnancy, breastfeeding and plans to conceive all affect whether treatment is appropriate at all.

If you are curious about the broader evidence, including a fuller breakdown of which are the fastest weight loss injections across the options currently available in the UK, that page covers safety profile, eligibility and what to expect month by month. You can also read a more detailed comparison of which weight loss injection works the best, weighing up the clinical data across all the options currently used in UK practice. For questions specific to your situation, our FAQs address the most common ones, and our clinical team can be reached through the consultation process. Both medicines are reviewed at NICE technology appraisal TA1026 (tirzepatide) and TA875 (semaglutide), which set out the eligibility thresholds used across UK clinical practice.

Speed is a reasonable thing to want. A prescriber is the right person to tell you which option is likely to get you there, safely, and at the right dose for your body. Check your eligibility and one of our GPhC-registered prescribers will review your consultation the same day.